CBX3 and hepatocellular carcinoma: In conclusion, our findings demonstrated that KCNQ1OT1 weakened the antitumor effects of SEVO on HCC progression through modulating the miR-29a-3p/CBX3 axis, providing a potential target for the therapy of HCC patients.